Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Evaluate the Effect of PEGASYS on ALT and HBV DNA Levels in Patients With Lamivudine-Resistant HbeAg-Negative Chronic Hepatitis B

NCT00460850 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00460850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00460850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Evaluate the Effect of PEGASYS on ALT and HBV DNA Levels in Patients With Lamivudine-Resistant HbeAg-Negative Chronic Hepatitis B
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Terminated
Start date
September 30, 2007
Completion date
June 30, 2008
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, chronic